Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) pioneers regenerative medicine solutions through its plant-based recombinant human collagen (rhCollagen) technology. This dedicated news hub provides investors and stakeholders with timely updates on clinical advancements, strategic partnerships, and product developments in 3D bioprinting, medical aesthetics, and tissue repair.
Access official press releases covering regulatory milestones, research breakthroughs, and commercial collaborations with industry leaders like AbbVie and Stratasys. Our curated collection includes updates on Vergenix™ wound care products, rhCollagen BioInk applications, and progress in regenerative breast implant development.
Discover comprehensive coverage of financial results, intellectual property expansions, and manufacturing scale-up initiatives. This resource serves as your primary source for tracking CollPlant's progress in addressing unmet needs across orthobiologics, advanced wound care, and organ manufacturing markets.
Bookmark this page for streamlined access to CLGN's latest developments in biocompatible medical solutions. Check regularly for updates on ESG initiatives, patent filings, and clinical trial outcomes that shape the company's position in the $3B+ regenerative medicine sector.
CollPlant (NASDAQ: CLGN) announced its financial results for the year ended December 31, 2020, revealing significant growth with revenues of $6.1 million, a 165% increase from $2.3 million in 2019. The company entered a strategic agreement worth up to $103 million with Allergan Aesthetics, which included an upfront payment of $14 million. Despite an operating loss of $5.6 million, a 36% decrease from the previous year, CollPlant ended the year with $49 million in cash reserves. The company's ongoing innovations include developing 3D bioprinted breast implants.
CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced that CEO Yehiel Tal will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation, covering a corporate overview, will be available on-demand starting at 7 a.m. EST on March 9. CollPlant specializes in 3D bioprinting of tissues and medical aesthetics, leveraging its proprietary rhCollagen technology. The company recently partnered with Allergan for dermal and soft tissue fillers, enhancing its market position.
CollPlant Biotechnologies (NASDAQ: CLGN) announced the termination of its licensing agreement with Lung Biotechnology on February 24, 2021. This collaboration focused on developing bioprinting scaffolds for lung transplants. CEO Yehiel Tal emphasized advancements in their rhCollagen-based BioInks, which are key in regenerative medicine. CollPlant's ongoing projects include partnerships with tier-one companies and a significant agreement with Allergan for dermal and soft tissue fillers. Despite these developments, the termination of a key agreement may impact future prospects.
CollPlant Biotechnologies (NASDAQ: CLGN) reported a transformative 2020, with unaudited revenues of approximately $6 million, a 160% increase from 2019. The advancements stemmed from strategic collaborations, including partnerships with Allergan and United Therapeutics. Notably, Allergan's agreement utilizes CollPlant's recombinant human collagen for aesthetic applications, while the expanded deal with United Therapeutics addresses organ transplant shortages. The company maintains robust cash reserves of $50 million and no debt, reinforcing its growth potential as it enhances its regenerative medicine pipeline.
CollPlant Biotechnologies (NASDAQ:CLGN) has successfully closed a registered direct offering of 2,000,000 American Depositary Shares (ADSs) priced at $17.50 each, raising gross proceeds of $35.0 million. The funds will be utilized for general corporate purposes, including working capital and the development of regenerative and aesthetic medicine products. The offering is conducted under a shelf registration statement filed with the SEC. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
CollPlant Biotechnologies (NASDAQ:CLGN) announced a registered direct offering of 2,000,000 American Depositary Shares (ADSs) at $17.50 each, aiming to raise approximately $35 million in gross proceeds. The offering is expected to close around February 17, 2021. The net proceeds will support general corporate purposes, including working capital and the development of regenerative medicine products. H.C. Wainwright & Co. is the exclusive placement agent for this offering.
CollPlant Biotechnologies (NASDAQ: CLGN) has secured a worldwide exclusive development and commercialization agreement with Allergan Aesthetics, part of AbbVie, for dermal and soft tissue filler products. This agreement includes an upfront payment of $14 million and potential milestone payments of up to $89 million. Allergan will utilize CollPlant's plant-derived recombinant human collagen (rhCollagen) alongside its own technologies. CEO Yehiel Tal expressed optimism for a transformative partnership, targeting a market expected to reach $10 billion by 2026.
CollPlant (NASDAQ: CLGN) has entered into a product manufacturing and supply agreement with STEMCELL Technologies, Canada's largest biotechnology company. This partnership involves the sale of CollPlant's recombinant human Type I collagen (rhCollagen) for use in cell culture media kits developed by STEMCELL. This agreement builds on their existing business relationship since 2014, aiming to enhance regenerative medicine research. STEMCELL's global distribution of these kits is expected to advance applications in stem cells, cancer, and cellular therapy.
CollPlant (NASDAQ: CLGN) reported a remarkable 511% increase in revenues for Q3 2020, totaling $4.1 million, up from $679,000 in Q3 2019. The company's comprehensive income reached $703,000 on a GAAP basis, or $1.1 million non-GAAP, significantly improving from a loss of $3.2 million in the same quarter last year. Cash and equivalents stood at $5.0 million. The strong financial performance is attributed to the collaboration with United Therapeutics and advancements in medical aesthetics.
CollPlant (NASDAQ: CLGN) announced the early development of an antiviral agent utilizing its recombinant human type I collagen (rhCollagen) embedded with silver nanoparticles (AgNP) for potential COVID-19 treatment. Initial in-vitro results show significant inhibition of avian coronavirus infectivity, a model for SARS-CoV-2. The company plans to develop an inhalation formulation aimed at protecting respiratory systems, which could help reduce transmission and severity of COVID-19.
